SCHEMBL5755993

SCHEMBL5755993

O=C(NO)[C@@H](Cc1ccccc1)NS(=O)(=O)c1ccc2nc(SCC3CCCCC3)sc2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 6/20 0.48
MMP9 P14780 5/20 0.48
ALDH1A1 P00352 3/20 0.44
LMNA P02545 1/20 0.44
HSP90AA1 P07900 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
MCL1 Q07820 1/20 0.43
MEN1 O00255 1/20 0.43
CYP2C9 P11712 1/20 0.43
KMT2A Q03164 1/20 0.43
F2 P00734 2/20 0.42
NPY5R Q15761 1/20 0.42
ITGB3 P05106 1/20 0.41
ITGAV P06756 1/20 0.41
MMP13 P45452 1/20 0.41
POLB P06746 1/20 0.41
MMP3 P08254 1/20 0.41
MMP10 P09238 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5755972 0.93 POLB (0.48) MMP2MMP9ALDH1A1LMNAHSP90AA1
SCHEMBL5755212 0.87 ALDH1A1 (0.51) ALDH1A1LMNAHSP90AA1HPGDTSHR
SCHEMBL5755594 0.85 ALDH1A1 (0.48) ALDH1A1LMNAHSP90AA1HPGDTSHR
SCHEMBL5756907 0.85 LMNA (0.44) ALDH1A1LMNAHSP90AA1HPGDTSHR
SCHEMBL5756642 0.83 SMN1; SMN2 (0.50) ALDH1A1LMNAHSP90AA1HPGDTSHR
SCHEMBL5757499 0.82 MMP2 (0.50) MMP2MMP9LMNAMEN1CYP2C9
SCHEMBL5754992 0.81 MMP2 (0.49) MMP2MMP9LMNAMEN1CYP2C9
SCHEMBL5757798 0.81 LMNA (0.52) ALDH1A1LMNAHSP90AA1HPGDTSHR
SCHEMBL5760236 0.81 ALDH1A1 (0.39) MMP2MMP9ALDH1A1LMNAHSP90AA1
SCHEMBL5756059 0.80 RXFP1 (0.50) MMP2MMP9ALDH1A1LMNAHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1208092-B1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2006-06-21 EP disclosed
US-6548667-B2 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase SAMSUNG ELECTRONICS CO. LTD. (KR) 2003-04-15 US disclosed
EP-1208092-A4 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO LTD (KR) 2003-01-02 EP disclosed
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor SAMSUNG ELECTRONICS CO. LTD. (KR) 2002-11-14 US disclosed
EP-1208092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2002-05-29 EP disclosed
WO-2001077092-A1 SULFONAMIDE DERIVATIVE AS A MATRIX METALLOPROTEINASE INHIBITOR SAMSUNG ELECTRONICS CO., LTD. (KR) 2001-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169314-A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor MMP9, MMP3, MMP14 MMP2 8/4885MMP9 1/4885ALDH1A1 311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.